MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy

MIRA Pharmaceuticals, a clinical-stage company listed on NASDAQ, has released positive findings for Ketamir-2, its oral ketamine analog, in treating diabetic neuropathy in animal models. These results come as MIRA advances its Phase I study, with Phase IIa trials planned by year-end 2025. The study, conducted on diabetic rats, showed Ketamir-2's potential in significantly reducing neuropathic pain, with some subjects achieving complete symptom reversal.

CEO Erez Aminov emphasized the demand for safer, non-opioid treatments for diabetic neuropathy, a condition affecting a large percentage of diabetes patients. By avoiding dissociative effects and efficiently penetrating the blood-brain barrier, Ketamir-2 shows promise as a potent alternative to existing neuropathic pain medications.